As COL6A3 is essential in facilitating tumor progression and metastasis, future studies targeting COL6A3 as a valuable biomarker for the early diagnosis of chemotherapy drug resistance, metastasis, recurrence, and the prediction of survival outcome by checking COL6A3 exosomes from the blood, ascites, or tissues of EOC patients are warranted, and the mediation of possible related signaling should be explored. The gene discussed is COL6A3; the disease is neoplasm.